Medical devices comprise electronic equipment, implants, consumables and disposables, surgical instruments and in-vitro ...
19h
Corbus Pharmaceuticals presented Phase 1 data on CRB-701 at ASCO GU, showing safety, tolerability, and responses across multiple tumor types.
Pfizer hopes a unique life-extension benefit for its Talzenna can serve to further expand the drug’s already ...
One concern with bispecific antibody therapies in community settings is managing adverse events, with emerging patterns ...
Casas, MD, discusses a systematic review of recent trials examining objective response rate and adverse events of antibody drug conjugate (ADC) combinations in advanced urothelial cancer.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback